FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, namely to monoclonal antibody immunospecifically binding to human PSGL-1, pharmaceutical composition for treating a disorder or disease associated with or caused by increased proliferation and/or an increased number of activated T cells, as well as to method of treating an inflammatory disorder with their use. Also disclosed are kits for treating a disorder or disease associated with or caused by increased proliferation and/or an increased number of activated T cells containing the above antibody.
EFFECT: invention allows to effectively treat inflammatory disorders.
18 cl, 7 dwg, 11 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-KIT ANTIBODIES AND USES THEREOF | 2013 |
|
RU2681730C2 |
| TETRAVALENT ANTIBODIES TO PSGL-1 AND THEIR APPLICATIONS | 2017 |
|
RU2766000C2 |
| MONOCLONAL ANTIBODIES BINDING WITH hGM-CSF AND COMPOSITIONS FOR MEDICINAL PURPOSES, CONTAINING THEREOF | 2008 |
|
RU2517596C2 |
| ANTIBODIES | 2005 |
|
RU2482131C2 |
| METHODS OF TREATING PSORIASIS | 2008 |
|
RU2475265C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| ANTI-LAG-3 ANTIBODIES | 2016 |
|
RU2760582C2 |
| HUMAN VISTA ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2746994C2 |
| PEPTIDE OR PEPTIDE COMPLEX BINDING TO alpha2- INTEGRIN, METHODS FOR PRODUCTION AND USE THEREOF | 2011 |
|
RU2588668C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
